Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Timothy Rolph Sells 12,500 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Timothy Rolph sold 12,500 shares of the firm's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $44.53, for a total value of $556,625.00. Following the completion of the sale, the insider now directly owns 170,237 shares in the company, valued at approximately $7,580,653.61. The trade was a 6.84 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Timothy Rolph also recently made the following trade(s):

• On Wednesday, February 5th, Timothy Rolph sold 18,750 shares of Akero Therapeutics stock. The stock was sold at an average price of $56.51, for a total value of $1,059,562.50.
• On Monday, January 27th, Timothy Rolph sold 31,250 shares of Akero Therapeutics stock. The shares were sold at an average price of $55.77, for a total value of $1,742,812.50.
• On Tuesday, December 10th, Timothy Rolph sold 4,818 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.91, for a total value of $148,924.38.

Akero Therapeutics Stock Performance

AKRO stock traded up $0.92 during midday trading on Tuesday, reaching $42.60. The stock had a trading volume of 513,440 shares, compared to its average volume of 845,423. Akero Therapeutics, Inc. has a 52-week low of $17.86 and a 52-week high of $58.40. The stock has a market cap of $3.39 billion, a PE ratio of -11.34 and a beta of -0.19. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. The firm has a fifty day simple moving average of $40.77 and a two-hundred day simple moving average of $33.39.

Remove Ads

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.01). As a group, equities research analysts anticipate that Akero Therapeutics, Inc. will post -3.99 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Summit Investment Advisors Inc. increased its holdings in shares of Akero Therapeutics by 6.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company's stock valued at $197,000 after purchasing an additional 450 shares in the last quarter. Hsbc Holdings PLC grew its position in Akero Therapeutics by 8.5% during the fourth quarter. Hsbc Holdings PLC now owns 7,886 shares of the company's stock valued at $220,000 after buying an additional 621 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Akero Therapeutics by 1.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 41,442 shares of the company's stock valued at $1,153,000 after buying an additional 637 shares in the last quarter. Handelsbanken Fonder AB raised its holdings in Akero Therapeutics by 5.0% in the 4th quarter. Handelsbanken Fonder AB now owns 21,000 shares of the company's stock worth $584,000 after purchasing an additional 1,000 shares during the period. Finally, Swiss National Bank raised its stake in shares of Akero Therapeutics by 1.2% during the 4th quarter. Swiss National Bank now owns 95,600 shares of the company's stock worth $2,660,000 after buying an additional 1,100 shares during the period.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on AKRO. Bank of America raised shares of Akero Therapeutics from a "neutral" rating to a "buy" rating and increased their price target for the stock from $35.00 to $63.00 in a research note on Thursday, January 30th. Citigroup increased their price objective on Akero Therapeutics from $65.00 to $80.00 and gave the company a "buy" rating in a research report on Tuesday, January 28th. UBS Group boosted their target price on shares of Akero Therapeutics from $42.00 to $109.00 and gave the company a "buy" rating in a research note on Friday, January 31st. HC Wainwright boosted their target price on shares of Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research report on Monday, March 3rd. Finally, Morgan Stanley reissued an "overweight" rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $76.29.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.